CD274 and neoplasm: Despite our ability to use predictive biomarkers such as PD-L1 (Programmed cell death ligand 1) expression and a high TMB (tumor mutational burden) as indicators for ICIs treatment, the widespread clinical use of ICIs is limited by various constraints (13, 14).